# Diabetes Research Hub — Monitor Report

**Generated:** 2026-05-14 (automated scheduled run)
**Scan window:** since previous monitor report (2026-05-13)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`

---

## 1. File System Status

| File | Last Modified | Age | Status |
|---|---|---|---|
| `Analysis/Results/hub_monitor_report.md` | 2026-05-14 07:05 | <1d | OK (fresh) |
| `Analysis/Results/clinical_trials_latest.json` | 2026-05-14 07:04 | <1d | OK (fresh) |
| `Analysis/Results/pubmed_recent_latest.json` | 2026-05-14 07:05 | <1d | OK (fresh) |
| `Analysis/Results/literature_gap_report.md` | 2026-05-13 14:19 | 1d | OK |
| `Analysis/Results/literature_gap_data.json` | 2026-04-20 15:35 | **24d** | **STALE (>14d)** |
| `Analysis/Results/agent_state.json` | 2026-05-13 14:20 | 1d | OK |
| `Research_Findings_Summary.md` | 2026-05-13 14:20 | 1d | OK |
| `Diabetes_Research_Tracker.xlsx` | 2026-04-17 14:50 | 27d | Stale — consider refresh |

The hub_monitor scan reports **3 new files** and **29 modified files** since 2026-05-13, with **563 result files older than 14 days** flagged for possible refresh. New files are the daily snapshot rotation (clinical_trials, pubmed, monitor_report). No removed files.

---

## 2. Clinical Trial Changes

**Universe:** 793 tracked trials (T1D cell therapy 152 · T1D immunotherapy 72 · T2D novel 140 · Devices 221 · Recently completed w/ results 280).

### Δ vs. yesterday (2026-05-13)
- **New:** 3 trials added (1 newly-indexed Phase 3, 2 completed legacy studies pulled in by registry).
  - **NCT04333823** — Adolescent T1D Treatment with SGLT2i for Hyperglycemia & Hyperfiltration (The Hospital for Sick Children) — **PHASE 3 / ACTIVE_NOT_RECRUITING**. Relevant to T1D adjunct-SGLT2 line of research; track for results posting.
  - NCT04286555 — DASH for Diabetes (Johns Hopkins, NA, completed)
  - NCT04226027 — Dynamically Tailored Behavioral Interventions (Columbia, NA, completed)
- **Removed:** 1 trial (routine registry de-listing)
- **Status changes (1):** **NCT07379333** HM11260C (efpeglenatide-class, long-acting GLP-1) NOT_YET_RECRUITING → **RECRUITING**. Worth flagging — adds another Phase 3 GLP-1 entrant.
- **New results posted since yesterday:** 0.

### Δ vs. 7 days ago (2026-05-07)
- 10 new trials, **3 of them Phase 3**:
  - **NCT07581145** — Semaglutide on Healing of Foot Ulcers in T2D (PI: Ole Lander Svendsen) — RECRUITING. Novel indication for semaglutide.
  - **NCT04333823** — Adolescent T1D + SGLT2i (above).
  - **NCT05514535** — Novo Nordisk PHASE 3 semaglutide + lower-dose insulin glargine — **COMPLETED, results posted 2026-05-11**. Top item to review.
- No additional newly-posted results across the prior week.

### Phase 3 / Recruiting — High-Value Cohort
46 Phase 3 trials are recruiting overall. The Vertex VX-880 Phase 3 program (NCT04786262, NCT06832410) and Sanofi/Provention's teplizumab Phase 3 (NCT07088068) remain the highest-priority entries to track. Eli Lilly's baricitinib Phase 3 program (NCT07222137, NCT07222332) for delaying Stage 3 T1D is active and important. Tirzepatide T1D long-term study (NCT06962280) is ACTIVE_NOT_RECRUITING — watch for primary completion.

### Trials with Results Posted in Last 30 Days — Highlights
- **2026-05-11 NCT05514535** Novo Nordisk PHASE 3, semaglutide + glargine in T2D — *highest priority* (industry, Phase 3, results-now).
- **2026-05-12 NCT05454891** Extended bolus for meals in closed-loop AID (UCSF) — relevant to Closed Loop AP domain.
- **2026-05-04 NCT03940209** Addressing basic needs to improve diabetes outcomes (Medicaid) — Phase 2, health-equity relevant.

---

## 3. PubMed Highlights

**Snapshot:** 145 unique papers across 16 alert domains (30-day lookback). 40 papers are new since 2026-05-13; 99 new since 2026-05-07.

### Domain activity (last 30d)
- High volume: Diabetes AI/ML (199 total), Diabetes Biomarker (151), T2D GLP-1 New (143), Diabetes Microbiome (122), T2D Remission (68).
- Low volume (worth noting): T1D Stem Cell Cure (20), T1D Immunotherapy (17), Closed Loop AP (16), Diabetes Epigenetics (7), Drug Repurposing (6), LADA (5), GLP-1 Pharmacogenomics (1). The persistent very-low LADA and GLP-1 pharmacogenomics signal aligns with the standing literature-gap finding.

### Cross-Domain Papers (highest-priority, ≥2 domains)
13 cross-domain hits. The most actionable:

| PMID | Date | Title (truncated) | Domains |
|---|---|---|---|
| 42123550 | 2026-04-29 | Operon™ platform for cardiometabolic biomarker screening (T2D) | Biomarker · Microbiome · Multi-Omics |
| 42051156 | 2026-04-29 | **Considerations for clinical use of teplizumab in Stage 2 T1D — BDA Consensus** | T1D Immunotherapy · Key therapy: teplizumab |
| 42104727 | 2026-05-09 | Stem cell-based therapies for T1D: differentiation, clinical translation, immune protection | T1D Stem Cell · Gene Therapy |
| 42128231 | 2026-05-12 | GLP-1RA-like effects of Bafetinib (in vitro + in vivo) | T2D GLP-1 · **Drug Repurposing** |
| 42108331 | 2026-05-11 | Automated insulin delivery in advanced CKD (Diabetologia) | T2D Remission · Closed Loop AP |
| 42129562 | 2026-05-13 | Sleep chart of biological ageing clocks (Nature) | AI/ML · Multi-Omics |
| 42089665 | 2026-05-06 | VEGFA-targeted ionizable LNPs for diabetic retinopathy | Gene Therapy · Complications |

### Key Therapy Mentions
| Therapy | Papers (30d) | Notable |
|---|---|---|
| **orforglipron** | 3 | PMID 42120723 — Phase 3b ATTAIN-MAINTENANCE (orforglipron, body-weight maintenance, randomized DB) — **flag for tracker**; PMID 42116665 — GI safety analysis |
| **teplizumab** | 3 | PMID 42051156 — **BDA Consensus Statement** for Stage 2 use; PMID 41796109 & 41535597 — real-world adult data |
| **icodec** | 2 | PMID 42119975 — **pooled T1D+T2D safety profile**; PMID 41705603 — cost-utility (China) |
| **retatrutide** | 1 | PMID 42108533 — review of triple-agonism in CKM (cardiovascular-kidney-metabolic) |
| **baricitinib** | 1 | Case report (dermatologic) — not diabetes-relevant |
| **zimislecel / VX-880 / CagriSema** | 0 | No PubMed activity in window — surprising given ongoing Phase 3 activity; possibly indexed under VX-880 only in trial registry |

---

## 4. Gap Analysis Summary

(Gap data file is **24 days old** — re-run recommended. Gap report markdown is current as of 2026-05-13.)

### Top 5 Ranked Gaps (Bronze validation level)
1. **Beta Cell Regen × Health Equity** — gap 100, 0 joint pubs (expected ~1,615)
2. **Insulin Resistance × Islet Transplant** — gap 100, 1 joint pub
3. **Islet Transplant × GWAS / Polygenic** — gap 100 *(classified as methodologically distinct — likely deprioritize)*
4. **Islet Transplant × Drug Repurposing** — gap 100, 0 joint pubs
5. **Islet Transplant × Health Equity** — gap 100, 0 joint pubs

### Alignment with Tier 1 Doctrine Areas
Multiple top gaps map directly onto Tier 1 contribution areas:
- **Drug Repurposing × Islet Transplant** and **Drug Repurposing × LADA** sit inside Tier 1 #4 (Drug Repurposing Screening). The Bafetinib/GLP-1RA paper this week (PMID 42128231) is a concrete instance — a kinase inhibitor showing GLP-1RA-like activity is exactly the kind of repurposing signal the doctrine targets.
- **Health Equity × Beta Cell Regen / Islet Transplant / Treg-CAR-T** spans Tier 1 #6 (Epidemiology). Access-equity analysis of advanced cell/immune therapies remains a wide-open lane.
- **Islet Transplant × Insulin Resistance** intersects Tier 1 #1 (Multi-Omics Biomarker Integration) if framed via post-transplant metabolic phenotyping.

---

## 5. Breaking News (Last 7 Days, Web Verified)

- **FDA approval — Eli Lilly Foundayo™ (orforglipron)** — the first GLP-1 oral pill for weight loss with no food/water restrictions. Directly relevant: this matches the new Phase 3b PubMed result (PMID 42120723) and Lilly's Phase 3 obesity trials (NCT06972472 etc.).
- **FDA approval — Sanofi Tzield (teplizumab)** — expanded to delay Stage 3 T1D **in young children**. Pairs with the BDA Stage 2 Consensus paper (PMID 42051156) this week. Major item.
- **Langlara (insulin glargine-aldy)** — interchangeable biosimilar to Lantus approved 2026-04-29.
- **Novo Nordisk Ozempic® oral tablets (1.5/4/9 mg) available in US** as of 2026-05-04. Relevant context for icodec/oral semaglutide trial reads.
- **MannKind Afrezza pediatric PDUFA — 2026-05-29.** Watch for outcome — would be first needle-free pediatric insulin.
- **Preclinical: Chimeric immune-system + islet transplant in mice (Swedish group, May 2026)** — 19/19 prevention and 9/9 reversal. Promising but mouse-only; tag as **Bronze/Preclinical** per Research Doctrine — do not over-weight.

---

## 6. Recommended Actions

Prioritized:

1. **Update tracker with the Novo Nordisk Phase 3 result (NCT05514535)** — semaglutide + low-dose glargine in T2D, results posted 2026-05-11. This is the most actionable new evidence this cycle.
2. **Add Foundayo™ approval + orforglipron ATTAIN-MAINTENANCE (PMID 42120723) to Research_Findings_Summary.md.** GLP-1 oral landscape just shifted.
3. **Add teplizumab pediatric approval + BDA Consensus (PMID 42051156)** to T1D Immunotherapy section of tracker. Phase 3 NCT07088068 status remains RECRUITING — re-verify next cycle.
4. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. `literature_gap_data.json` is 24 days old; the gap report file was regenerated 2026-05-13 but its underlying counts are stale.
5. **Re-review Drug Repurposing × Beta Cell / Islet axis** in light of PMID 42128231 (Bafetinib GLP-1RA-like effect). This is the second repurposing signal in two weeks and is one of the Tier 1 contribution areas.
6. **Flag NCT07379333 (HM11260C) status change** to RECRUITING — adds a long-acting GLP-1 Phase 3 entrant; ensure it is captured in the GLP-1 New / Cardiometabolic dashboard.
7. **Diabetes_Research_Tracker.xlsx is 27 days old** — schedule a manual sync against the live trial + therapy data this week.
8. **No script runs needed** — all four monitor data files exist and (except gap_data) are current.

---

## 7. Evidence-Level Tags

Per the Research Doctrine, claims surfaced in this report carry the following levels:

- ClinicalTrials.gov / PubMed-indexed status changes: **Silver** (single authoritative source, public registry).
- New FDA approvals (press release + cross-confirmed): **Gold** once cross-referenced with FDA Drugs@FDA listing — not yet verified in this run; treat as **Silver** until confirmed.
- Cross-domain PubMed hits: **Bronze** until at least one independent replication is in hand.
- Gap-analysis rankings: **Bronze** (single bibliometric source; see report caveats).
- Preclinical mouse-only news items: **Bronze / preclinical**.

---

*Run produced autonomously by the diabetes-hub-monitor scheduled task. No source files were modified.*
